This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Bintrafusp alfa
DrugBank Accession Number
DB15387
Background

Bintrafusp alfa is under investigation in clinical trial NCT03833661 (M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)).

Type
Biotech
Groups
Investigational
Synonyms
  • Bintrafusp alfa

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
NW9K8C1JN3
CAS number
1918149-01-5

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Not Yet RecruitingTreatmentLung Cancers / Other Cancers1
2Active Not RecruitingTreatmentBiliary Tract Cancer (BTC) / Cancer of the Gallbladder / Cholangiocarcinomas1
2Active Not RecruitingTreatmentBreast Neoplasms, Triple-Negative1
2Active Not RecruitingTreatmentUterine Cervical Neoplasms1
2Not Yet RecruitingTreatmentAdvanced Soft Tissue Sarcoma (STS) / Metastatic Soft Tissue Sarcoma1
2Not Yet RecruitingTreatmentBladder Cancer, Cancer / Transitional Cell, Carcinoma1
2Not Yet RecruitingTreatmentEsthesioneuroblastoma / Neoplasm of the Nasal Cavity / Olfactory Neuroblastoma1
2Not Yet RecruitingTreatmentImmunotherapy / Nasopharyngeal Carcinoma (NPC) / NPC1
2Not Yet RecruitingTreatmentMesothelioma; Lung1
2RecruitingTreatmentAdvanced Non-Small Cell Lung Carcinoma / Stage III Lung Cancer AJCC v8 / Stage IIIA Lung Cancer AJCC v8 / Stage IIIB Lung Cancer AJCC v8 / Stage IIIC Lung Cancer AJCC v8 / Stage IV Lung Cancer AJCC v8 / Stage IVA Lung Cancer AJCC v8 / Stage IVB Lung Cancer AJCC v81

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at May 20, 2019 15:23 / Updated at February 21, 2021 18:55